Specifically, examining the effects of natural and synthetic FFAR1- and FFAR4-specific agonists in treating NAFLD, NASH, and IFALD are promising avenues that warrant further investigation. This evidence concerns the gene FFAR1 and metabolic dysfunction-associated steatotic liver disease.